GB9620795D0 - Vaccines - Google Patents

Vaccines

Info

Publication number
GB9620795D0
GB9620795D0 GBGB9620795.6A GB9620795A GB9620795D0 GB 9620795 D0 GB9620795 D0 GB 9620795D0 GB 9620795 A GB9620795 A GB 9620795A GB 9620795 D0 GB9620795 D0 GB 9620795D0
Authority
GB
United Kingdom
Prior art keywords
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9620795.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to GBGB9620795.6A priority Critical patent/GB9620795D0/en
Publication of GB9620795D0 publication Critical patent/GB9620795D0/en
Priority claimed from US09/819,464 external-priority patent/US20010053365A1/en
Application status is Pending legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse Transcribing DNA Viruses
    • C12N2730/00011—Reverse Transcribing DNA Viruses
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse Transcribing RNA Viruses
    • C12N2740/00011—Reverse Transcribing RNA Viruses
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
    • C12N2740/11034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38—Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/408—Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa
    • Y02A50/411—Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria
    • Y02A50/412—Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46—Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/462—The waterborne disease being caused by a virus
    • Y02A50/463—The waterborne disease being caused by a virus the virus being the Hepatitis A virus [HAV]
    • Y02A50/464—The waterborne disease being caused by a virus the virus being the Hepatitis A virus [HAV] the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
GBGB9620795.6A 1996-10-05 1996-10-05 Vaccines Pending GB9620795D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GBGB9620795.6A GB9620795D0 (en) 1996-10-05 1996-10-05 Vaccines

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
GBGB9620795.6A GB9620795D0 (en) 1996-10-05 1996-10-05 Vaccines
CA002267191A CA2267191A1 (en) 1996-10-05 1997-09-30 Vaccines
EP97910430A EP0939650A1 (en) 1996-10-05 1997-09-30 Vaccines
KR1019990702874A KR20000048866A (en) 1996-10-05 1997-09-30 Vaccines
HU9904549A HU9904549A3 (en) 1996-10-05 1997-09-30 Vaccines
PCT/EP1997/005578 WO1998015287A1 (en) 1996-10-05 1997-09-30 Vaccines
PL97332633A PL332633A1 (en) 1996-10-05 1997-09-30 Vaccines
TR1999/00729T TR199900729T2 (en) 1996-10-05 1997-09-30 vaccinations
IL12898597A IL128985D0 (en) 1996-10-05 1997-09-30 Vaccines
CZ991167A CZ116799A3 (en) 1996-10-05 1997-09-30 Adjuvant preparation and vaccine
CN97180166A CN1238696A (en) 1996-10-05 1997-09-30 Vaccines
JP10517196A JP2001501640A (en) 1996-10-05 1997-09-30 vaccine
BR9711853A BR9711853A (en) 1996-10-05 1997-09-30 vaccines
NZ334734A NZ334734A (en) 1996-10-05 1997-09-30 Vaccine composition comprising alum, a saponin fraction (QS21), a sterol (cholesterol), SUV (liposome forming) and MPL (3-de-O-acylated monophosphoryl lipid A)
AU47812/97A AU714930B2 (en) 1996-10-05 1997-09-30 Vaccines
CO97057863A CO4910170A1 (en) 1996-10-05 1997-10-03 vaccines
ARP970104569A AR009958A1 (en) 1996-10-05 1997-10-03 adjuvant compositions; vaccines formulated with such compositions; the use of such compositions in the preparation of vaccines and parapreparar procedure such vaccines.
ZA9708868A ZA9708868B (en) 1996-10-05 1997-10-03 Vaccine composition
NO991524A NO991524L (en) 1996-10-05 1999-03-29 vaccinations
US09/819,464 US20010053365A1 (en) 1995-04-25 2001-03-28 Vaccines
US13/162,134 US20110243971A1 (en) 1995-04-25 2011-06-16 Vaccines

Publications (1)

Publication Number Publication Date
GB9620795D0 true GB9620795D0 (en) 1996-11-20

Family

ID=10800990

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9620795.6A Pending GB9620795D0 (en) 1996-10-05 1996-10-05 Vaccines

Country Status (19)

Country Link
EP (1) EP0939650A1 (en)
JP (1) JP2001501640A (en)
KR (1) KR20000048866A (en)
CN (1) CN1238696A (en)
AR (1) AR009958A1 (en)
AU (1) AU714930B2 (en)
BR (1) BR9711853A (en)
CA (1) CA2267191A1 (en)
CO (1) CO4910170A1 (en)
CZ (1) CZ116799A3 (en)
GB (1) GB9620795D0 (en)
HU (1) HU9904549A3 (en)
IL (1) IL128985D0 (en)
NO (1) NO991524L (en)
NZ (1) NZ334734A (en)
PL (1) PL332633A1 (en)
TR (1) TR199900729T2 (en)
WO (1) WO1998015287A1 (en)
ZA (1) ZA9708868B (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU734180B2 (en) * 1997-08-29 2001-06-07 Antigenics Llc Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9817052D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
AU750587B2 (en) * 1998-10-16 2002-07-25 Smithkline Beecham Biologicals (Sa) Adjuvant systems and vaccines
AU769539B2 (en) 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
CA2370697C (en) 1999-04-19 2012-03-06 Smithkline Beecham Biologicals S.A. Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
AT534401T (en) 2000-10-18 2011-12-15 Glaxosmithkline Biolog Sa Mage antigen coupled to a protein d fragment containing vaccines
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
CZ20021074A3 (en) 1999-09-24 2002-08-14 Nihon Nohyaku Co., Ltd. Derivatives of aromatic diamides and salts thereof, agricultural and horticultural preparations and method for using them
DK1227837T3 (en) 1999-10-22 2008-09-15 Aventis Pasteur Method for introducing and / or speeding up an immune response to a tumor antigen
AU772617B2 (en) * 1999-11-19 2004-05-06 Csl Limited Vaccine compositions
US6905712B2 (en) 1999-12-08 2005-06-14 Statens Veterinarmedicinska Anstalt Vaccine adjuvants comprising ginseng plant extract and added aluminum salt
WO2001041802A1 (en) * 1999-12-08 2001-06-14 Statens Veterinärmedicinska Anstalt Vaccine adjuvants comprising ginseng plant extract and added aluminium salt
EP1741782B1 (en) 2000-05-10 2011-06-22 Sanofi Pasteur Limited Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
AU2002254901A1 (en) 2001-02-23 2002-10-03 Smithkline Beecham Biologicals S.A. Influenza vaccine formulations for intradermal delivery
EP1361889A1 (en) * 2001-02-23 2003-11-19 GlaxoSmithKline Biologicals S.A. Novel vaccine
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0123580D0 (en) * 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
EP1537418A2 (en) 2002-09-13 2005-06-08 Intercell AG Method for isolating hepatitis c virus peptides
AU2003254585A1 (en) 2002-07-24 2004-02-16 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
CA2502268A1 (en) 2002-10-23 2004-05-06 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
EP1608401A1 (en) * 2003-03-24 2005-12-28 Intercell AG Use of alum and a th1 immune response inducing adjuvant for enhancing immune respones
CA2517673C (en) 2003-03-24 2013-08-13 Intercell Ag Improved vaccines for preventing viral infection
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
GB0519871D0 (en) 2005-09-30 2005-11-09 Secr Defence Immunogenic agents
HUE041979T2 (en) 2005-12-22 2019-06-28 Glaxosmithkline Biologicals Sa Pneumococcal polysaccharide conjugate vaccine
TWI457133B (en) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa Novel composition
AU2007233705B2 (en) 2006-03-30 2010-12-23 Glaxosmithkline Biologicals S.A. Immunogenic composition
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
NZ574239A (en) 2006-07-18 2011-12-22 Glaxosmithkline Biolog Sa Hybrid fusion proteins for malaria vaccines
US8323664B2 (en) 2006-07-25 2012-12-04 The Secretary Of State For Defence Live vaccine strains of Francisella
US9040081B2 (en) 2006-11-20 2015-05-26 Duecom Use of lipid containing particles comprising Quillaja saponins for the treatment of cancer
PT2137210T (en) 2007-03-02 2017-01-09 Glaxosmithkline Biologicals Sa Novel method and compositions
SI2167121T1 (en) 2007-06-26 2015-12-31 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
BRPI0815199A2 (en) 2007-08-13 2015-03-31 Glaxosmithkline Biolog Sa Use of an antigen derived from plasmodium falciparum circumsporozyte protein
AU2008352942B2 (en) 2007-12-19 2013-09-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Soluble forms of Hendra and Nipah virus F glycoprotein and uses thereof
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB0900455D0 (en) 2009-01-13 2009-02-11 Secr Defence Vaccine
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
WO2010092479A2 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with reduced amounts of squalene
ES2671880T3 (en) 2009-03-05 2018-06-11 Jenny Colleen Mccloskey Infection Treatment
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
MX2012011189A (en) 2010-03-26 2013-02-07 Glaxosmithkline Biolog Sa Hiv vaccine.
US20130259948A1 (en) 2010-09-21 2013-10-03 National Institute Of Immunology Spray dried powder formulation for vaccines entrapping alum and the antigen in biodegradable polymer particles
BR112013004582A2 (en) 2010-09-27 2016-09-06 Crucell Holland Bv method for inducing an immune response in a subject against a parasite antigen that causes malaria
US20140348844A1 (en) 2011-09-16 2014-11-27 Ucb Pharma S.A. Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
JP2019528072A (en) 2016-08-23 2019-10-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Fusion peptide in which antigen is linked to small fragment of invariant chain (CD74)
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
BE1024774B1 (en) 2016-09-29 2018-07-02 Glaxosmithkline Biologicals Sa Compositions and methods of treatment
BE1025160B1 (en) * 2016-12-07 2018-11-26 Glaxosmithkline Biologicals Sa New process
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
WO2018219521A1 (en) * 2017-05-30 2018-12-06 Glaxosmithkline Biologicals S.A. Methods for manufacturing an adjuvant
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9002314A (en) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogenic complexes, in particular iscoms.
HU220295B (en) * 1991-07-25 2001-11-28 Idec Pharmaceuticals Corp. Antigen formulations and their use to induce cytotoxic T-lymphocyte responses in
EP0692974B2 (en) * 1993-03-29 2007-05-30 Pfizer Inc. Multicomponent clostridial vaccines using saponin adjuvants
CA2217178C (en) * 1995-04-25 2009-09-29 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol

Also Published As

Publication number Publication date
TR199900729T2 (en) 1999-07-21
CZ116799A3 (en) 1999-08-11
WO1998015287A1 (en) 1998-04-16
CN1238696A (en) 1999-12-15
IL128985D0 (en) 2000-02-17
KR20000048866A (en) 2000-07-25
AU4781297A (en) 1998-05-05
AR009958A1 (en) 2000-05-17
NZ334734A (en) 2000-05-26
NO991524D0 (en) 1999-03-29
BR9711853A (en) 1999-08-24
ZA9708868B (en) 1999-04-06
JP2001501640A (en) 2001-02-06
AU714930B2 (en) 2000-01-13
CA2267191A1 (en) 1998-04-16
EP0939650A1 (en) 1999-09-08
NO991524L (en) 1999-03-29
PL332633A1 (en) 1999-09-27
CO4910170A1 (en) 2000-04-24
HU9904549A (en) 2000-05-28
HU9904549A3 (en) 2001-06-28

Similar Documents

Publication Publication Date Title
DE69732794D1 (en) Expandierbare endoluminale prothesen
DE69730298D1 (en) Koerpertemperaturmessvorrichtung
DK0904360T3 (en) Alpha-amylasemutanter
DE69730525D1 (en) Optoakustische thrombolyse
DE69738449D1 (en) Video-hyperlinks
DE69722940D1 (en) Intravaskuläre prothese
TW575566B (en) Cycloalkano-pyridines
DE69735767D1 (en) Cellulasevarianten
DE69730360D1 (en) Expandierbarer osteosynthesekäfig
DE69734818D1 (en) Digitales stromdifferentialsystem
DE69634986D1 (en) Modulares wandlersystem
DE69703502D1 (en) Larynx-intubationsgerät
DE69715838D1 (en) Thermomorphe drucksensitive klebmittel
DE69608577D1 (en) Thermostabiler schalldämmstoff
DE69711882D1 (en) Carbolinderivate
DE69729315D1 (en) Aminopyrazolderivate
DE69730533D1 (en) Irrigationsvorrichtung
DE69619551D1 (en) Rohrisolation
DE69733322D1 (en) Glycosidase-enzyme
DE69728152D1 (en) Hoch-lipophile campothecin-derivate
DE69734361D1 (en) Luftreinigungsfilter
DE69733813D1 (en) Implantierbare hörprothese
DE69708059D1 (en) Thiophenopyrimidine
DE69702926D1 (en) Polyurethanhartschäume
DE69705420D1 (en) Polyurethanhartschäume